D Watkins1, N Matiaszuk, D S Rosenblatt. 1. Division of Medical Genetics, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada. dwatkins@generation.net
Abstract
AIM: To investigate genetic heterogeneity within the cblA class of inborn error of cobalamin metabolism. CONTEXT: The cblA disorder is characterised by vitamin B12 (cobalamin) responsive methylmalonic aciduria and deficient synthesis of adenosylcobalamin, required for activity of the mitochondrial enzyme methylmalonyl CoA mutase. The cblA gene has not been identified or cloned. We have previously described a patient with the clinical and biochemical phenotype of the cblA disorder whose fibroblasts complemented cells from patients with all known types of inborn error of adenosylcobalamin synthesis, including cblA. METHODS: We have performed somatic cell complementation analysis of the cblA variant fibroblast line with a panel of 28 cblA lines. We have also performed detailed complementation analysis on a panel of 10 cblA fibroblast lines, not including the cblA variant line. RESULTS: The cblA variant line complemented all 28 cell lines of the panel. There was evidence for interallelic complementation among the 10 cblA lines used for detailed complementation analysis; no cell line in this panel complemented all other members. CONCLUSIONS: These results strongly suggest that the cblA variant represents a novel complementation class, which we have designated cblH and which represents a mutation at a distinct gene. They also suggest that the cblA gene encodes a protein that functions as a multimer, allowing for extensive interallelic complementation.
AIM: To investigate genetic heterogeneity within the cblA class of inborn error of cobalamin metabolism. CONTEXT: The cblA disorder is characterised by vitamin B12 (cobalamin) responsive methylmalonic aciduria and deficient synthesis of adenosylcobalamin, required for activity of the mitochondrial enzyme methylmalonyl CoA mutase. The cblA gene has not been identified or cloned. We have previously described a patient with the clinical and biochemical phenotype of the cblA disorder whose fibroblasts complemented cells from patients with all known types of inborn error of adenosylcobalamin synthesis, including cblA. METHODS: We have performed somatic cell complementation analysis of the cblA variant fibroblast line with a panel of 28 cblA lines. We have also performed detailed complementation analysis on a panel of 10 cblA fibroblast lines, not including the cblA variant line. RESULTS: The cblA variant line complemented all 28 cell lines of the panel. There was evidence for interallelic complementation among the 10 cblA lines used for detailed complementation analysis; no cell line in this panel complemented all other members. CONCLUSIONS: These results strongly suggest that the cblA variant represents a novel complementation class, which we have designated cblH and which represents a mutation at a distinct gene. They also suggest that the cblA gene encodes a protein that functions as a multimer, allowing for extensive interallelic complementation.
Authors: F Watanabe; H Saido; R Yamaji; K Miyatake; Y Isegawa; A Ito; T Yubisui; D S Rosenblatt; Y Nakano Journal: J Nutr Date: 1996-12 Impact factor: 4.798
Authors: C Melissa Dobson; Timothy Wai; Daniel Leclerc; Aaron Wilson; Xuchu Wu; Carole Doré; Thomas Hudson; David S Rosenblatt; Roy A Gravel Journal: Proc Natl Acad Sci U S A Date: 2002-11-15 Impact factor: 11.205
Authors: Frank Rutsch; Susann Gailus; Isabelle R Miousse; Terttu Suormala; Corinne Sagné; Mohammad Reza Toliat; Gudrun Nürnberg; Tanja Wittkampf; Insa Buers; Azita Sharifi; Martin Stucki; Christian Becker; Matthias Baumgartner; Horst Robenek; Thorsten Marquardt; Wolfgang Höhne; Bruno Gasnier; David S Rosenblatt; Brian Fowler; Peter Nürnberg Journal: Nat Genet Date: 2009-01-11 Impact factor: 38.330
Authors: C Lee Elmore; Xuchu Wu; Daniel Leclerc; Erica D Watson; Teodoro Bottiglieri; Natalia I Krupenko; Sergey A Krupenko; James C Cross; Rima Rozen; Roy A Gravel; Rowena G Matthews Journal: Mol Genet Metab Date: 2007-03-21 Impact factor: 4.797
Authors: Paula J Waters; Fanny Thuriot; Joe T R Clarke; Serge Gravel; David Watkins; David S Rosenblatt; Sébastien Lévesque Journal: Mol Genet Metab Rep Date: 2016-09-24